RecruitingPhase 2NCT07637448

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

32 participants

Start Date

May 21, 2026

Study Type

INTERVENTIONAL

Conditions

EGFR Activating Mutation Lung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody

Summary

This study is an open-label, multicenter, single-arm clinical study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EGFR-TKIs Combined with PD-1 Monoclonal Antibody for people with egfr activating mutation, lung cancer non-small cell cancer (nsclc), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.